Castrate resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor and AR splicing variants that become resistant to established hormonal therapy strategies such as enzalutamide.
Zhipeng Wang +11 more
doaj +1 more source
Objective Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC).
Takashi Kawahara +5 more
doaj +1 more source
Practical guide to the use of enzalutamide.
INTRODUCTION: We summarize the development, definitive trials, and practical use of enzalutamide for practicing urologists and medical oncologists. The care paradigm for patients with metastatic castration resistant prostate cancer (mCRPC) is a changing ...
Hoffman-Censits, Jean, Kelly, Wm Kevin
core
Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer
Androgen deprivation is the standard treatment for patients with prostate cancer. However, the disease eventually progresses as castration-resistant prostate cancer (CRPC). Enzalutamide, an androgen receptor inhibitor, is a typical drug for treating CRPC
Liu, Jinpeng +5 more
core +1 more source
Metastatic prostate cancer (mPCa) is a leading cause of mortality, partly due to its resistance to anti-androgens like enzalutamide. Snail can promote this resistance by increasing full-length AR and AR-V7.
Taaliah Campbell +4 more
core +1 more source
Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors. [PDF]
Siskin M +5 more
europepmc +1 more source
Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort. [PDF]
Manova M +11 more
europepmc +1 more source
Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study. [PDF]
Corona G +5 more
europepmc +1 more source
Development and Validation of an HPLC-MS/MS Method for Determining BMS-1166, GB-1107, and Enzalutamide in Rat Plasma and Its Application to Pharmacokinetic Studies. [PDF]
Wang S, Lu S, Li G, Qi Y.
europepmc +1 more source
Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions. [PDF]
Rival PM +5 more
europepmc +1 more source

